Market Overview:
The global gabapentin drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for pain relief drugs. In addition, the increasing use of gabapentin in off-label indications is also contributing to the growth of this market. Based on type, the global gabapentin drug market can be segmented into capsules, tablets, and oral solutions. Capsules are expected to account for a major share of this market owing to their ease of use and high patient compliance rates. By application, postherpetic neuralgia in adults is expected to account for a major share of this market due its high prevalence rate across all regions.
Product Definition:
Gabapentin is a prescription drug used to treat seizures, nerve pain, and restless legs syndrome. It belongs to a class of drugs called anticonvulsants. Gabapentin works by decreasing abnormal activity in the brain.
Capsule:
Capsule is a small container that holds the medicine and it's used to administer drugs. It can be oral, transdermal or topical. Capsules are mostly used for drug delivery to ensure the safety of the medication and prevent unwanted side effects on the patient. The size of capsule depends upon two factors: type of drug (enteric or non-enteric) and dosage form (capsule filled with powder, liquid fillings).
Tablet:
Tablet is a form of drug delivery technology that has gained popularity in the pharmaceutical industry. It is a solid dosage form for drugs, which are mostly administered to patients by mouth. The most commonly used types of tablets are film-coated, effervescent, and chewable tablets. Tablets have several advantages such as they can be easily divided into smaller doses; they provide accurate dosing at the recommended level; and they offer better patient compliance owing to their easy handling characteristics.
Application Insights:
On the basis of application, the global gabapentin drug market has been segmented into postherpetic neuralgia in adults, partial onset seizures, others and unmet medical needs. The postherpetic neuralgia in adults segment held the largest share of over 30% in 2017. This is attributed to a high incidence rate of this condition coupled with awareness campaigns conducted by various public and private organizations to increase patient awareness about treatment options for PN.
The partial onsets seizure segment is anticipated to witness lucrative growth during the forecast period owing to increasing incidence rates of epilepsy coupled with rising demand for anticonvulsant drugs worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing Gabapentin prescriptions are some of the factors responsible for its largest share. In addition, rising incidence of postherpetic neuralgia and other applications is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness fastest growth during the forecast period owing to growing number of patients suffering from neuropathic pain due to diabetes or other causes as well as increased awareness about treatment options for these conditions among patients & physicians. Moreover, availability & accessibility Gabapentin products through online pharmacies will also boost market development in this region over next eight years.
Growth Factors:
- Increasing incidence of chronic pain: The global prevalence of chronic pain is estimated to be around 20%, and it is projected to increase to 30% by 2030. This will create a large pool of patients who will require treatment, including for Gabapentin drug therapy.
- Rising geriatric population: The number of people aged 65 years or older is increasing rapidly, and this segment accounts for a growing proportion of the population with chronic conditions that can benefit from Gabapentin drug therapy.
- Growing awareness about Gabapentin drugs: There is growing awareness among healthcare professionals and patients about the benefits of using Gabapentin drugs for various indications, which is likely to drive increased demand for these medications in the coming years.
- Availability of generic versions: A number of generic versions are available in most markets, which helps make these medications more affordable and accessible to patients who need them.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gabapentin Drug Market Research Report
By Type
Capsule, Tablet, Oral Solution
By Application
Postherpetic Neuralgia in Adults, Partial Onset Seizures, Others
By Companies
Pfizer, Depomed, Apotex, Teva, Acella Pharmaceuticals, Taro, Sun Pharmaceutical, Glenmark, Amneal Pharmaceuticals, Aurobindo Pharma, Pfizer, Hi-Tech Pharmaceuticals, Marksans Pharma, Mylan, InvaGen Pharmaceuticals, Alkem Laboratories, Tris Pharma, ACI HealthCare Limited, Jiangsu Hengrui Medicine, CSPC Ouyi Pharmaceutical, Sciegen Pharmaceuticals, Epic Pharma, Lupin Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Gabapentin Drug Market Report Segments:
The global Gabapentin Drug market is segmented on the basis of:
Types
Capsule, Tablet, Oral Solution
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Postherpetic Neuralgia in Adults, Partial Onset Seizures, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Depomed
- Apotex
- Teva
- Acella Pharmaceuticals
- Taro
- Sun Pharmaceutical
- Glenmark
- Amneal Pharmaceuticals
- Aurobindo Pharma
- Pfizer
- Hi-Tech Pharmaceuticals
- Marksans Pharma
- Mylan
- InvaGen Pharmaceuticals
- Alkem Laboratories
- Tris Pharma
- ACI HealthCare Limited
- Jiangsu Hengrui Medicine
- CSPC Ouyi Pharmaceutical
- Sciegen Pharmaceuticals
- Epic Pharma
- Lupin Limited
Highlights of The Gabapentin Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablet
- Oral Solution
- By Application:
- Postherpetic Neuralgia in Adults
- Partial Onset Seizures
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gabapentin Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gabapentin is a medication used to treat seizures and other conditions. It is also used to relieve pain. Gabapentin works by affecting the brain and nervous system.
Some of the key players operating in the gabapentin drug market are Pfizer, Depomed, Apotex, Teva, Acella Pharmaceuticals, Taro, Sun Pharmaceutical, Glenmark, Amneal Pharmaceuticals, Aurobindo Pharma, Pfizer, Hi-Tech Pharmaceuticals, Marksans Pharma, Mylan, InvaGen Pharmaceuticals, Alkem Laboratories, Tris Pharma, ACI HealthCare Limited, Jiangsu Hengrui Medicine, CSPC Ouyi Pharmaceutical, Sciegen Pharmaceuticals, Epic Pharma, Lupin Limited.
The gabapentin drug market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gabapentin Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gabapentin Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gabapentin Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gabapentin Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gabapentin Drug Market Size & Forecast, 2020-2028
4.5.1 Gabapentin Drug Market Size and Y-o-Y Growth
4.5.2 Gabapentin Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Capsule
5.2.2 Tablet
5.2.3 Oral Solution
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Postherpetic Neuralgia in Adults
6.2.2 Partial Onset Seizures
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gabapentin Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gabapentin Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Capsule
9.6.2 Tablet
9.6.3 Oral Solution
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Postherpetic Neuralgia in Adults
9.10.2 Partial Onset Seizures
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Capsule
10.6.2 Tablet
10.6.3 Oral Solution
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Postherpetic Neuralgia in Adults
10.10.2 Partial Onset Seizures
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Capsule
11.6.2 Tablet
11.6.3 Oral Solution
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Postherpetic Neuralgia in Adults
11.10.2 Partial Onset Seizures
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Capsule
12.6.2 Tablet
12.6.3 Oral Solution
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Postherpetic Neuralgia in Adults
12.10.2 Partial Onset Seizures
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Capsule
13.6.2 Tablet
13.6.3 Oral Solution
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Postherpetic Neuralgia in Adults
13.10.2 Partial Onset Seizures
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gabapentin Drug Market: Competitive Dashboard
14.2 Global Gabapentin Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Depomed
14.3.3 Apotex
14.3.4 Teva
14.3.5 Acella Pharmaceuticals
14.3.6 Taro
14.3.7 Sun Pharmaceutical
14.3.8 Glenmark
14.3.9 Amneal Pharmaceuticals
14.3.10 Aurobindo Pharma
14.3.11 Pfizer
14.3.12 Hi-Tech Pharmaceuticals
14.3.13 Marksans Pharma
14.3.14 Mylan
14.3.15 InvaGen Pharmaceuticals
14.3.16 Alkem Laboratories
14.3.17 Tris Pharma
14.3.18 ACI HealthCare Limited
14.3.19 Jiangsu Hengrui Medicine
14.3.20 CSPC Ouyi Pharmaceutical
14.3.21 Sciegen Pharmaceuticals
14.3.22 Epic Pharma
14.3.23 Lupin Limited
